Design of controlled-release morphine suppositories containing polyglycerol ester of fatty acid

Toshihito Takatori, Kazumitsu Yamamoto, Toshikazu Yamaguchi, Kazutaka Higaki, Toshikiro Kimura

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Controlled-release morphine suppositories were prepared by utilizing polyglycerol ester of fatty acid (PGEF). The addition of PGEF to fatty suppository base Witepsol H15 resulted in a decrease of morphine release rate from suppositories. Among PGEFs examined, decaglycerol heptabehenate (HB750) was the most effective additive for the controlled-release of morphine from fatty suppositories. The apparent viscosity of suppository bases increased with the increase in HB750 content, and good correlation was observed between the apparent viscosity of suppository bases at 37° C and the amount of HB750 added in the mixed base. The in vitro release rate of morphine was decreased by the addition of HB750 and the release rate constant (Higuchi's rate constant) for morphine release was significantly correlated with the HB750 content in the mixed bases as well as the apparent viscosity of mixed bases, indicating that the release of morphine from the mixed bases could be regulated by the HB750 content in the mixed bases. After rectal administration of Witepsol H-15-HB750 mixed suppositories to dogs, plasma concentrations of morphine did not increase rapidly at early time periods, but relatively high levels of morphine in plasma were sustained for longer time periods. Mean residence time of morphine was considerably prolonged without changing relative bioavailability in the case of the mixed base suppositories containing 15-17% HB750, compared with the Witepsol H15 suppository, clearly indicating that the mixed bases containing HB750 are expected to be useful for the design of controlled-release morphine suppositories.

Original languageEnglish
Pages (from-to)1480-1484
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume28
Issue number8
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Suppositories
Morphine
Esters
Fatty Acids
Viscosity
polyglycerol
Rectal Administration
Biological Availability
Dogs

Keywords

  • Fatty suppository
  • Morphine suppository
  • Polyglycerol ester of fatty acid
  • Release control
  • Viscosity

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Design of controlled-release morphine suppositories containing polyglycerol ester of fatty acid. / Takatori, Toshihito; Yamamoto, Kazumitsu; Yamaguchi, Toshikazu; Higaki, Kazutaka; Kimura, Toshikiro.

In: Biological and Pharmaceutical Bulletin, Vol. 28, No. 8, 08.2005, p. 1480-1484.

Research output: Contribution to journalArticle

Takatori, Toshihito ; Yamamoto, Kazumitsu ; Yamaguchi, Toshikazu ; Higaki, Kazutaka ; Kimura, Toshikiro. / Design of controlled-release morphine suppositories containing polyglycerol ester of fatty acid. In: Biological and Pharmaceutical Bulletin. 2005 ; Vol. 28, No. 8. pp. 1480-1484.
@article{d986262880544908acd253b723adf4bd,
title = "Design of controlled-release morphine suppositories containing polyglycerol ester of fatty acid",
abstract = "Controlled-release morphine suppositories were prepared by utilizing polyglycerol ester of fatty acid (PGEF). The addition of PGEF to fatty suppository base Witepsol H15 resulted in a decrease of morphine release rate from suppositories. Among PGEFs examined, decaglycerol heptabehenate (HB750) was the most effective additive for the controlled-release of morphine from fatty suppositories. The apparent viscosity of suppository bases increased with the increase in HB750 content, and good correlation was observed between the apparent viscosity of suppository bases at 37° C and the amount of HB750 added in the mixed base. The in vitro release rate of morphine was decreased by the addition of HB750 and the release rate constant (Higuchi's rate constant) for morphine release was significantly correlated with the HB750 content in the mixed bases as well as the apparent viscosity of mixed bases, indicating that the release of morphine from the mixed bases could be regulated by the HB750 content in the mixed bases. After rectal administration of Witepsol H-15-HB750 mixed suppositories to dogs, plasma concentrations of morphine did not increase rapidly at early time periods, but relatively high levels of morphine in plasma were sustained for longer time periods. Mean residence time of morphine was considerably prolonged without changing relative bioavailability in the case of the mixed base suppositories containing 15-17{\%} HB750, compared with the Witepsol H15 suppository, clearly indicating that the mixed bases containing HB750 are expected to be useful for the design of controlled-release morphine suppositories.",
keywords = "Fatty suppository, Morphine suppository, Polyglycerol ester of fatty acid, Release control, Viscosity",
author = "Toshihito Takatori and Kazumitsu Yamamoto and Toshikazu Yamaguchi and Kazutaka Higaki and Toshikiro Kimura",
year = "2005",
month = "8",
doi = "10.1248/bpb.28.1480",
language = "English",
volume = "28",
pages = "1480--1484",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "8",

}

TY - JOUR

T1 - Design of controlled-release morphine suppositories containing polyglycerol ester of fatty acid

AU - Takatori, Toshihito

AU - Yamamoto, Kazumitsu

AU - Yamaguchi, Toshikazu

AU - Higaki, Kazutaka

AU - Kimura, Toshikiro

PY - 2005/8

Y1 - 2005/8

N2 - Controlled-release morphine suppositories were prepared by utilizing polyglycerol ester of fatty acid (PGEF). The addition of PGEF to fatty suppository base Witepsol H15 resulted in a decrease of morphine release rate from suppositories. Among PGEFs examined, decaglycerol heptabehenate (HB750) was the most effective additive for the controlled-release of morphine from fatty suppositories. The apparent viscosity of suppository bases increased with the increase in HB750 content, and good correlation was observed between the apparent viscosity of suppository bases at 37° C and the amount of HB750 added in the mixed base. The in vitro release rate of morphine was decreased by the addition of HB750 and the release rate constant (Higuchi's rate constant) for morphine release was significantly correlated with the HB750 content in the mixed bases as well as the apparent viscosity of mixed bases, indicating that the release of morphine from the mixed bases could be regulated by the HB750 content in the mixed bases. After rectal administration of Witepsol H-15-HB750 mixed suppositories to dogs, plasma concentrations of morphine did not increase rapidly at early time periods, but relatively high levels of morphine in plasma were sustained for longer time periods. Mean residence time of morphine was considerably prolonged without changing relative bioavailability in the case of the mixed base suppositories containing 15-17% HB750, compared with the Witepsol H15 suppository, clearly indicating that the mixed bases containing HB750 are expected to be useful for the design of controlled-release morphine suppositories.

AB - Controlled-release morphine suppositories were prepared by utilizing polyglycerol ester of fatty acid (PGEF). The addition of PGEF to fatty suppository base Witepsol H15 resulted in a decrease of morphine release rate from suppositories. Among PGEFs examined, decaglycerol heptabehenate (HB750) was the most effective additive for the controlled-release of morphine from fatty suppositories. The apparent viscosity of suppository bases increased with the increase in HB750 content, and good correlation was observed between the apparent viscosity of suppository bases at 37° C and the amount of HB750 added in the mixed base. The in vitro release rate of morphine was decreased by the addition of HB750 and the release rate constant (Higuchi's rate constant) for morphine release was significantly correlated with the HB750 content in the mixed bases as well as the apparent viscosity of mixed bases, indicating that the release of morphine from the mixed bases could be regulated by the HB750 content in the mixed bases. After rectal administration of Witepsol H-15-HB750 mixed suppositories to dogs, plasma concentrations of morphine did not increase rapidly at early time periods, but relatively high levels of morphine in plasma were sustained for longer time periods. Mean residence time of morphine was considerably prolonged without changing relative bioavailability in the case of the mixed base suppositories containing 15-17% HB750, compared with the Witepsol H15 suppository, clearly indicating that the mixed bases containing HB750 are expected to be useful for the design of controlled-release morphine suppositories.

KW - Fatty suppository

KW - Morphine suppository

KW - Polyglycerol ester of fatty acid

KW - Release control

KW - Viscosity

UR - http://www.scopus.com/inward/record.url?scp=25644434759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25644434759&partnerID=8YFLogxK

U2 - 10.1248/bpb.28.1480

DO - 10.1248/bpb.28.1480

M3 - Article

VL - 28

SP - 1480

EP - 1484

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 8

ER -